[go: up one dir, main page]

CY2023016I2 - Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του - Google Patents

Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Info

Publication number
CY2023016I2
CY2023016I2 CY2023016C CY2023016C CY2023016I2 CY 2023016 I2 CY2023016 I2 CY 2023016I2 CY 2023016 C CY2023016 C CY 2023016C CY 2023016 C CY2023016 C CY 2023016C CY 2023016 I2 CY2023016 I2 CY 2023016I2
Authority
CY
Cyprus
Prior art keywords
polypeptide
production
modified factor
factor
modified
Prior art date
Application number
CY2023016C
Other languages
English (en)
Other versions
CY2023016I1 (el
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2023016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of CY2023016I1 publication Critical patent/CY2023016I1/el
Publication of CY2023016I2 publication Critical patent/CY2023016I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY2023016C 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του CY2023016I2 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
EP17175191.0A EP3252157A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
EP09748260.8A EP2337849B1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (2)

Publication Number Publication Date
CY2023016I1 CY2023016I1 (el) 2024-02-16
CY2023016I2 true CY2023016I2 (el) 2024-02-16

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20231100138T CY1125885T1 (el) 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
CY2023016C CY2023016I2 (el) 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20231100138T CY1125885T1 (el) 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Country Status (19)

Country Link
US (13) USRE50288E1 (el)
EP (5) EP2337849B1 (el)
CA (1) CA2737094C (el)
CY (2) CY1125885T1 (el)
DK (2) DK3581650T3 (el)
ES (3) ES2985035T3 (el)
FI (5) FI3581650T3 (el)
FR (4) FR23C1028I1 (el)
HK (1) HK1244507A1 (el)
HR (2) HRP20230259T1 (el)
HU (6) HUE067487T2 (el)
LT (5) LT3581650T (el)
NO (2) NO2023029I1 (el)
PL (3) PL2337849T3 (el)
PT (1) PT3581650T (el)
SI (1) SI3581650T1 (el)
SM (2) SMT202300084T1 (el)
TR (1) TR201813067T4 (el)
WO (1) WO2010029178A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2985035T3 (es) * 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
BR112015001628A2 (pt) 2012-07-25 2017-11-07 Catalyst Biosciences Inc polipeptídeos de fator x modificados e uso dos mesmos
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL256517B2 (en) 2015-06-23 2024-06-01 Childrens Hospital Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
MX2019000962A (es) 2016-07-26 2019-08-01 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado.
CN116355883A (zh) * 2016-10-14 2023-06-30 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
AR112057A1 (es) 2017-05-22 2019-09-18 Baxalta Inc Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
EP4488288A3 (en) 2017-07-10 2025-04-16 uniQure IP B.V. Means and methods for aav gene therapy in humans
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
JP2021523198A (ja) 2018-05-14 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド 幼若対象におけるａａｖベクターの安定的発現
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
SG11202101560QA (en) * 2018-08-20 2021-03-30 Ucl Business Ltd Factor ix encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CN113260701A (zh) 2018-10-18 2021-08-13 英特利亚治疗股份有限公司 用于表达因子ix的组合物和方法
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
US20240293516A1 (en) * 2021-07-01 2024-09-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety
WO2025022005A1 (en) * 2023-07-26 2025-01-30 Le Quellec Sandra Intranasal administration of factor ix polypeptides

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380848D1 (en) 1982-08-04 1989-12-21 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
DE59711957D1 (de) 1996-06-11 2004-10-28 Roche Diagnostics Gmbh Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ATE455552T1 (de) 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6610906B1 (en) 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
WO2002004544A2 (en) 2000-07-06 2002-01-17 Guilford Pharmaceuticals Polymers and polymerization processes
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
RU2004110239A (ru) 2001-09-04 2005-10-20 Мерк Патент ГмбХ (DE) Модифицированный фактор ix
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en) 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
ZA200502867B (en) 2002-10-02 2007-09-26 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
DK2277996T3 (da) 2003-05-21 2014-10-20 Genzyme Corp Fremgangsmåder til fremstilling af præparationer af rekombinante aav-virioner, der i hovedsagen er fri for tomme capsider
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP1781782B1 (en) 2004-08-17 2010-05-26 CSL Behring GmbH Modified vitamin k dependent polypeptides
DE502004008275D1 (de) 2004-08-19 2008-11-27 Gerd Baer Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
ES2381796T3 (es) 2004-09-22 2012-05-31 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
US20070172846A1 (en) 2005-11-12 2007-07-26 Introgen Therapeutics, Inc. Methods for the Production and Purification of Adenoviral Vectors
EP1791039A1 (fr) 2005-11-25 2007-05-30 The Swatch Group Research and Development Ltd. Spiral en verre athermique pour mouvement d'horlogerie et son procédé de fabrication
CA2633661C (en) 2005-12-21 2019-06-04 University Of North Carolina At Chapel Hill Method of producing biologically active vitamin k dependent proteins by recombinant methods
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
EP1991257B1 (en) 2006-03-07 2015-05-06 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor ix
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US20070274908A1 (en) 2006-04-07 2007-11-29 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US20070280906A1 (en) 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
AU2008209985A1 (en) 2007-02-01 2008-08-07 Baxter Healthcare S.A. Improved fix-mutant proteins for hemophilia B treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
CN102083856A (zh) * 2008-04-16 2011-06-01 拜耳医药保健有限公司 经修饰的因子ix多肽及其用途
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
US8647620B2 (en) 2009-06-25 2014-02-11 The University Of North Carolina At Chapel Hill Chimeric factor VII molecules
CA2769258A1 (en) 2009-07-31 2011-02-03 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
CN108093639B (zh) 2015-04-16 2022-07-19 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
IL256517B2 (en) 2015-06-23 2024-06-01 Childrens Hospital Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
PE20250736A1 (es) 2016-04-15 2025-03-10 Univ Pennsylvania Terapia genica para tratar la hemofilia a
US11191847B2 (en) 2016-04-15 2021-12-07 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia B
EP4488288A3 (en) 2017-07-10 2025-04-16 uniQure IP B.V. Means and methods for aav gene therapy in humans
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
HUS2300024I1 (hu) 2023-08-28
EP4219547A2 (en) 2023-08-02
WO2010029178A1 (en) 2010-03-18
DK3581650T3 (da) 2023-03-13
US20180258413A1 (en) 2018-09-13
FIC20240036I1 (fi) 2024-10-29
FIC20230026I1 (fi) 2023-07-25
US20110244550A1 (en) 2011-10-06
EP2337849B1 (en) 2018-06-13
DK2337849T3 (en) 2018-10-01
EP3581650A2 (en) 2019-12-18
EP4032979B1 (en) 2024-05-01
HUE067487T2 (hu) 2024-10-28
FR24C1040I1 (fr) 2024-12-06
HK1244507A1 (en) 2018-08-10
FR25C1004I1 (fr) 2025-02-28
EP3581650A3 (en) 2020-03-25
TR201813067T4 (tr) 2018-09-21
ES2687038T3 (es) 2018-10-23
ES2985035T3 (es) 2024-11-04
CA2737094F (en) 2010-03-18
US20250179462A1 (en) 2025-06-05
LTPA2024530I1 (el) 2024-11-25
EP4219547A3 (en) 2023-10-18
US20160122740A1 (en) 2016-05-05
LTPA2023521I1 (el) 2023-08-25
EP4032979A1 (en) 2022-07-27
PL3581650T3 (pl) 2023-05-22
CA2737094C (en) 2018-02-20
HRP20230259T1 (hr) 2023-04-28
USRE50288E1 (en) 2025-02-04
US20220090042A1 (en) 2022-03-24
FIC20240037I1 (fi) 2024-10-30
US9982248B2 (en) 2018-05-29
EP4032979C0 (en) 2024-05-01
LTPA2025503I1 (el) 2025-02-10
US20200231958A1 (en) 2020-07-23
US20200190498A1 (en) 2020-06-18
ES2940323T3 (es) 2023-05-05
FR23C1028I1 (fr) 2023-10-06
PL2337849T3 (pl) 2018-11-30
HRP20181442T1 (hr) 2018-12-14
US9249405B2 (en) 2016-02-02
US20200199564A1 (en) 2020-06-25
US20210214704A1 (en) 2021-07-15
EP2337849A1 (en) 2011-06-29
PT3581650T (pt) 2023-03-08
SI3581650T1 (sl) 2023-06-30
HUS2500006I1 (hu) 2025-02-28
CY1125885T1 (el) 2024-02-16
US20170355973A1 (en) 2017-12-14
FIC20250007I1 (fi) 2025-01-22
EP3581650B1 (en) 2022-12-28
LTPA2024529I1 (el) 2024-12-10
EP3252157A1 (en) 2017-12-06
LT3581650T (lt) 2023-05-10
HUS2400036I1 (hu) 2024-11-28
HUE061345T2 (hu) 2023-06-28
FI3581650T3 (fi) 2023-03-23
NO2023029I1 (no) 2023-07-31
HUS2400037I1 (hu) 2024-11-28
CA2737094A1 (en) 2010-03-18
US10465180B2 (en) 2019-11-05
PL4032979T3 (pl) 2024-09-30
US20220002702A1 (en) 2022-01-06
SMT202300084T1 (it) 2023-05-12
CY2023016I1 (el) 2024-02-16
SMT201800468T1 (it) 2018-11-09
US20210238573A1 (en) 2021-08-05
NO2025007I1 (no) 2025-01-21
FR24C1041I1 (fr) 2024-12-06

Similar Documents

Publication Publication Date Title
CY2023016I1 (el) Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
BRPI0906752A2 (pt) promotor aprimorado e método para a produção de l-lisina usando o mesmo
NL2001649A1 (nl) Non-bolt joint structure and method for producing non-bolt joint structure.
BRPI0913227A2 (pt) método, e objeto
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
BRPI0921310A2 (pt) método para fabricar um compósito, compósito, e, aparelho
BRPI0916615A2 (pt) Construtos e métodos para a produção e secreção de polipeptídeos
BRPI0822112A8 (pt) sensor, método para detecção e método para produzir um sensor
FI20050257L (fi) Uudet merkinnät ja menetelmä niiden valmistamiseksi
EP2281932A4 (en) ARAMID CABLE AND METHOD FOR MANUFACTURING THE SAME
FI20075584A0 (fi) Menetelmä nosturin ohjaamiseksi
BRPI0813858A2 (pt) Método para produzir peptídeo
EP2160486A4 (en) NONWOVEN MAT AND METHOD FOR PRODUCING THE SAME
BRPI0718068A2 (pt) Material compósito, e, método
EP2006266A4 (en) Honeycomb structure, process for producing the same, and bonding material
DE602006016683D1 (de) Tonerherstellungsverfahren
BRPI0910880A2 (pt) mangueira compósita, e, método para produzir uma mangueira compósita.
DK2062053T3 (da) Forbedret immunoanalysefremgangsmåde
FI20050208L (fi) Menetelmä uusien tuotteiden valmistamiseksi
JP2010285712A5 (ja) ゴム物品補強用スチールコードおよびその製造方法
FI20080228L (fi) Menetelmä puu-muovikomposiittimateriaalin valmistamiseksi
FI20060460L (fi) Menetelmä terästuotannon yhteydessä
IT1394177B1 (it) Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
IT1395980B1 (it) Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
FI20075405A0 (fi) Menetelmä proteiinien uudelleenlaskostamiseksi